View in EDS

Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.

Saved in:
Bibliographic Details
Title: Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Authors: Postorino, M. C.1, Prosperi, M.2, Quiros-Roldan, E.3, Maggiolo, F.4, Di Giambenedetto, S.5, Saracino, A.6, Costarelli, S.7, Lorenzotti, S.8, Sighinolfi, L.9, Di Pietro, M.10, Torti, C.1 torti.carlo@libero.it
Source: Clinical Microbiology & Infection. Apr2015, Vol. 21 Issue 4, pe1-e9. 9p.
Database: Environment Complete
Description
ISSN:1198743X
DOI:10.1016/j.cmi.2014.10.022